Lantern Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Lantern Pharma Inc. (LTRN) on January 10, 2025, reporting events occurring on January 6, 2025. The company is a Delaware corporation with principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market. The filing addresses Item 5.02 regarding the amendment of an executive employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved amendments to the employment agreement for Kishor G. Bhatia, Chief Scientific Officer. The material changes include:
- Term Extension: The agreement term is extended until January 15, 2026.
- Time Commitment: Minimum hours devoted to the Company are adjusted to 24 hours per week.
- Compensation Adjustment: Annual base salary is proportionately adjusted to $189,600, effective with the first pay period in January 2025.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific executive compensation change.
Investor Verification Checklist
- Verify the effective date of the salary adjustment (January 2025 pay period).
- Confirm the total annual compensation package for the Chief Scientific Officer, including any equity or bonus components not detailed in this 8-K.
- Review the full amended employment agreement for termination clauses or other conditions.